{'fraction_non_alphanumeric': 0.03576341127922971, 'fraction_numerical': 0.001375515818431912, 'mean_word_length': 5.3304347826086955, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Gene expression profiling of breast cancer: a new tumor marker.

In ideal clinical oncology practice, one would like to have a single platform assay that can provide both prognostic (estimates of risk for failure after surgery alone) and predictive (estimate of benefit from specific therapy) information. Despite years of research, only estrogen receptors (ER), progesterone receptors, and HER-2 have been widely accepted for routine use in breast cancer, serving as predictive factors for endocrine and trastuzumab therapy, respectively. Until recently, new markers have been tested one, or at most two, at a time, a process that results in inefficient tissue usage, long delays in analysis, and, if positive, implementation.